Evenamide Phase 3 Program: Study 023 (ENIGMA-TRS) evaluates the efficacy of add-on glutamate modulation in patients with documented treatment-resistant schizophrenia

Neuroscience Applied 2026 Open access

Read full text

Authors: R. Anand, A. Turolla, G. Chinellato, F. Sansi, R. Hartman

DOI: 10.1016/j.nsa.2025.105757

Cited by: 0

Fields of Study & Subjects

Neuroscience and Neuropharmacology Research Schizophrenia research and treatment Neurotransmitter Receptor Influence on Behavior